Vergara will succeed and report to Brad Moore, who was recently appointed president and CEO of Roche Diagnostics North America. The position will continue to be based at Roche Diagnostics’ North American headquarters in Indianapolis.
In his time with Roche, Antonio has distinguished himself as a visionary change agent and a leader with diverse experiences and perspectives,” said Brad Moore, president and CEO of Roche Diagnostics North America. “He holds a deep understanding of our organization and portfolio given his strong financial background and broad business expertise.
Since starting his career with Roche Diagnostics Mexico as a financial controller 27 years ago, Vergara has built up an impressive breadth of experiences across Diagnostics and Pharmaceuticals. During this time, he has served in leadership roles spanning multiple countries, including Mexico, Canada, Puerto Rico, the United States, Central America and the Caribbean, Portugal, and Brazil. In 2018, he was appointed president, Roche Diagnostics Brazil, and has served in his current role as president and head of Roche Diagnostics Latin America since 2021.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.